A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo

Shih Hsin Tu, Hsing I. Huang, Su I. Lin, Hsin Yu Liu, Yuh Pyng Sher, Sheng Kuo Chiang, Pele Chong, Steve Roffler, Guan Chin Tseng, Hsin Wei Chen, Shih Jen Liu

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Vaccines utilizing cytotoxic T lymphocyte (CTL) epitopes are promising for the treatment of cancer and chronic infectious diseases. Tumor-associated antigen L6 (TAL6) is overexpressed in some epithelial cancer cells. In this report, we detected TAL6 expression in breast cancer tissue using quantitative reverse-transcriptase-polymerase chain reaction. We found that >80% of breast tumor tissue highly expressed TAL6 compared with adjacent normal breast tissue. To identify CTL epitopes from TAL6, we synthesized 18 peptides for HLA-A2-binding assay based on the MHC-binding motif using 4 computer prediction programs. Positive binders identified by ELISA were immunized in HLA-A2 transgenic (A2 Tg) mice. Two peptides, peptide 2 and peptide 5, induced T-cell responses in A2 Tg mice. To confirm whether these peptides could be processed and presented to induce T-cell responses in vivo, A2 Tg mice were immunized with plasmid DNA encoding TAL6. We found that both peptides 2 and 5 stimulated splenocytes from TAL6-immunized mice to secrete interferon-γ. However, only peptide 5 could induce expression of the cytolytic molecule CD107a on CD8 + T cells after immunization. Furthermore, peptide 5-immunized A2 Tg mice could inhibit the growth of TAL6-positive tumors (EL4/TAL6/HLA-A2) in A2 Tg mice but not in wild-type mice. These results demonstrate that the TAL6-derived CTL epitope could induce HLA-A2-restricted immunity against TAL6-expressing tumor cells.

Original languageEnglish
Pages (from-to)235-244
Number of pages10
JournalJournal of Immunotherapy
Volume35
Issue number3
DOIs
Publication statusPublished - Apr 2012

Fingerprint

HLA-A2 Antigen
T-Lymphocyte Epitopes
Cytotoxic T-Lymphocytes
Neoplasm Antigens
Growth
Peptides
Transgenic Mice
Neoplasms
varespladib methyl
T-Lymphocytes
Breast Neoplasms
Reverse Transcriptase Polymerase Chain Reaction
Interferons
Communicable Diseases
Immunity
Immunization
Breast
Plasmids
Chronic Disease
Software

Keywords

  • cytotoxic T lymphocytes
  • peptide
  • TAL6

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Cancer Research
  • Pharmacology

Cite this

A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo. / Tu, Shih Hsin; Huang, Hsing I.; Lin, Su I.; Liu, Hsin Yu; Sher, Yuh Pyng; Chiang, Sheng Kuo; Chong, Pele; Roffler, Steve; Tseng, Guan Chin; Chen, Hsin Wei; Liu, Shih Jen.

In: Journal of Immunotherapy, Vol. 35, No. 3, 04.2012, p. 235-244.

Research output: Contribution to journalArticle

Tu, SH, Huang, HI, Lin, SI, Liu, HY, Sher, YP, Chiang, SK, Chong, P, Roffler, S, Tseng, GC, Chen, HW & Liu, SJ 2012, 'A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo', Journal of Immunotherapy, vol. 35, no. 3, pp. 235-244. https://doi.org/10.1097/CJI.0b013e318248f2ae
Tu, Shih Hsin ; Huang, Hsing I. ; Lin, Su I. ; Liu, Hsin Yu ; Sher, Yuh Pyng ; Chiang, Sheng Kuo ; Chong, Pele ; Roffler, Steve ; Tseng, Guan Chin ; Chen, Hsin Wei ; Liu, Shih Jen. / A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo. In: Journal of Immunotherapy. 2012 ; Vol. 35, No. 3. pp. 235-244.
@article{b9e8a8cd1eea48ef9ac227465a2a33c1,
title = "A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo",
abstract = "Vaccines utilizing cytotoxic T lymphocyte (CTL) epitopes are promising for the treatment of cancer and chronic infectious diseases. Tumor-associated antigen L6 (TAL6) is overexpressed in some epithelial cancer cells. In this report, we detected TAL6 expression in breast cancer tissue using quantitative reverse-transcriptase-polymerase chain reaction. We found that >80{\%} of breast tumor tissue highly expressed TAL6 compared with adjacent normal breast tissue. To identify CTL epitopes from TAL6, we synthesized 18 peptides for HLA-A2-binding assay based on the MHC-binding motif using 4 computer prediction programs. Positive binders identified by ELISA were immunized in HLA-A2 transgenic (A2 Tg) mice. Two peptides, peptide 2 and peptide 5, induced T-cell responses in A2 Tg mice. To confirm whether these peptides could be processed and presented to induce T-cell responses in vivo, A2 Tg mice were immunized with plasmid DNA encoding TAL6. We found that both peptides 2 and 5 stimulated splenocytes from TAL6-immunized mice to secrete interferon-γ. However, only peptide 5 could induce expression of the cytolytic molecule CD107a on CD8 + T cells after immunization. Furthermore, peptide 5-immunized A2 Tg mice could inhibit the growth of TAL6-positive tumors (EL4/TAL6/HLA-A2) in A2 Tg mice but not in wild-type mice. These results demonstrate that the TAL6-derived CTL epitope could induce HLA-A2-restricted immunity against TAL6-expressing tumor cells.",
keywords = "cytotoxic T lymphocytes, peptide, TAL6",
author = "Tu, {Shih Hsin} and Huang, {Hsing I.} and Lin, {Su I.} and Liu, {Hsin Yu} and Sher, {Yuh Pyng} and Chiang, {Sheng Kuo} and Pele Chong and Steve Roffler and Tseng, {Guan Chin} and Chen, {Hsin Wei} and Liu, {Shih Jen}",
year = "2012",
month = "4",
doi = "10.1097/CJI.0b013e318248f2ae",
language = "English",
volume = "35",
pages = "235--244",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo

AU - Tu, Shih Hsin

AU - Huang, Hsing I.

AU - Lin, Su I.

AU - Liu, Hsin Yu

AU - Sher, Yuh Pyng

AU - Chiang, Sheng Kuo

AU - Chong, Pele

AU - Roffler, Steve

AU - Tseng, Guan Chin

AU - Chen, Hsin Wei

AU - Liu, Shih Jen

PY - 2012/4

Y1 - 2012/4

N2 - Vaccines utilizing cytotoxic T lymphocyte (CTL) epitopes are promising for the treatment of cancer and chronic infectious diseases. Tumor-associated antigen L6 (TAL6) is overexpressed in some epithelial cancer cells. In this report, we detected TAL6 expression in breast cancer tissue using quantitative reverse-transcriptase-polymerase chain reaction. We found that >80% of breast tumor tissue highly expressed TAL6 compared with adjacent normal breast tissue. To identify CTL epitopes from TAL6, we synthesized 18 peptides for HLA-A2-binding assay based on the MHC-binding motif using 4 computer prediction programs. Positive binders identified by ELISA were immunized in HLA-A2 transgenic (A2 Tg) mice. Two peptides, peptide 2 and peptide 5, induced T-cell responses in A2 Tg mice. To confirm whether these peptides could be processed and presented to induce T-cell responses in vivo, A2 Tg mice were immunized with plasmid DNA encoding TAL6. We found that both peptides 2 and 5 stimulated splenocytes from TAL6-immunized mice to secrete interferon-γ. However, only peptide 5 could induce expression of the cytolytic molecule CD107a on CD8 + T cells after immunization. Furthermore, peptide 5-immunized A2 Tg mice could inhibit the growth of TAL6-positive tumors (EL4/TAL6/HLA-A2) in A2 Tg mice but not in wild-type mice. These results demonstrate that the TAL6-derived CTL epitope could induce HLA-A2-restricted immunity against TAL6-expressing tumor cells.

AB - Vaccines utilizing cytotoxic T lymphocyte (CTL) epitopes are promising for the treatment of cancer and chronic infectious diseases. Tumor-associated antigen L6 (TAL6) is overexpressed in some epithelial cancer cells. In this report, we detected TAL6 expression in breast cancer tissue using quantitative reverse-transcriptase-polymerase chain reaction. We found that >80% of breast tumor tissue highly expressed TAL6 compared with adjacent normal breast tissue. To identify CTL epitopes from TAL6, we synthesized 18 peptides for HLA-A2-binding assay based on the MHC-binding motif using 4 computer prediction programs. Positive binders identified by ELISA were immunized in HLA-A2 transgenic (A2 Tg) mice. Two peptides, peptide 2 and peptide 5, induced T-cell responses in A2 Tg mice. To confirm whether these peptides could be processed and presented to induce T-cell responses in vivo, A2 Tg mice were immunized with plasmid DNA encoding TAL6. We found that both peptides 2 and 5 stimulated splenocytes from TAL6-immunized mice to secrete interferon-γ. However, only peptide 5 could induce expression of the cytolytic molecule CD107a on CD8 + T cells after immunization. Furthermore, peptide 5-immunized A2 Tg mice could inhibit the growth of TAL6-positive tumors (EL4/TAL6/HLA-A2) in A2 Tg mice but not in wild-type mice. These results demonstrate that the TAL6-derived CTL epitope could induce HLA-A2-restricted immunity against TAL6-expressing tumor cells.

KW - cytotoxic T lymphocytes

KW - peptide

KW - TAL6

UR - http://www.scopus.com/inward/record.url?scp=84863377785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863377785&partnerID=8YFLogxK

U2 - 10.1097/CJI.0b013e318248f2ae

DO - 10.1097/CJI.0b013e318248f2ae

M3 - Article

C2 - 22421941

AN - SCOPUS:84863377785

VL - 35

SP - 235

EP - 244

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 3

ER -